EUVIMEDEUVIMED entdecken
Crossref

Discovery of CCR8 Antagonist IDOR‐1136‐5177 for the Treatment of Cancer

Stefan Diethelm, Luboš Remeň, Hamed Aissaoui, Cédric Leroy, Alexia Chavanton-Arpel, Luca Docci, Swen Seeland, François Lehembre, Olivier Corminboeuf iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Stefan Diethelm und 8 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland. Hauptthemen laut MEDLINE: Receptors, CCR8, Drug Discovery, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CCR8 is a GPCR mainly expressed in tumor‐infiltrating T‐regulatory cells (Treg) and high CCR8 expression is associated with poor prognosis in cancer. CCR8 and its ligand CCL1 may be involved in Treg recruitment, conversion and/or immunosuppressive function. Recently, pharmacological inhibition of CCR8 in mouse models has been reported to result in tumor regression and small molecule inhibitors of CCR8 have entered the clinic. Aiming to find a new class of CCR8 antagonists, a high throughput screen (HTS) of the Idorsia compound library was performed. HTS hits with a promising profile were identified and subsequent characterization revealed hERG as a key parameter that required further optimization. We reasoned that a strategy focused on discrete structural modifications would offer significant potential to reduce hERG inhibition. The lead optimization campaign we report led to the identification of compound 52 (IDOR‐1136‐5177), a highly potent CCR8 antagonist representing a new chemical class of CCR8 inhibitors with excellent in vitro and in vivo properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR8Drug DiscoveryAntineoplastic AgentsNeoplasmsHumansAnimalsMiceStructure-Activity RelationshipMolecular StructureDose-Response Relationship, DrugDrug Screening Assays, AntitumorCell ProliferationHigh-Throughput Screening AssaysCell Line, Tumor

Stichwörter der Autor:innen

CCR8CancerGPCRTregshERG

Substanzen

Receptors, CCR8CCR8 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland.

ORCID-Profile: Olivier Corminboeuf

Zitieren

APA

Diethelm, S., Remeň, L., Aissaoui, H., Leroy, C., Chavanton-Arpel, A., Docci, L., Seeland, S., Lehembre, F., & Corminboeuf, O. (2025). Discovery of CCR8 Antagonist IDOR‐1136‐5177 for the Treatment of Cancer. ChemMedChem. https://doi.org/10.1002/cmdc.202400968

Vancouver

Diethelm S, Remeň L, Aissaoui H, Leroy C, Chavanton-Arpel A, Docci L, et al. Discovery of CCR8 Antagonist IDOR‐1136‐5177 for the Treatment of Cancer. ChemMedChem. 2025. doi:10.1002/cmdc.202400968

BibTeX
@article{Diethelm2025,
  author = {Diethelm, Stefan and Remeň, Luboš and Aissaoui, Hamed and Leroy, Cédric and Chavanton-Arpel, Alexia and Docci, Luca and Seeland, Swen and Lehembre, François and Corminboeuf, Olivier},
  title = {Discovery of CCR8 Antagonist IDOR‐1136‐5177 for the Treatment of Cancer},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400968}
}
Kostenlos starten →